A pair of phase 3 psoriasis studies of Alumis’ TYK2 inhibitor have hit their primary endpoints, setting the biotech up to file for approval of a potential challenger to Bristol Myers Squibb’s Sotyktu. With the news, Alumis’ shares more than doubled in premarket trading.
Espace publicitaire · 300×250
